-
Innovation Ranking
NewInnovation Ranking – Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company. It develops innovative medicines for the treatment of serious and life-threatening diseases. The company's clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Its products also include HSP90 modulators, RTA 901, RORγt inhibitors, and RTA 1701. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), alport syndrome and other kidney diseases; and omaveloxolone...
-
Product Insights
NewNet Present Value Model: Reata Pharmaceuticals Inc’s Omaveloxolone
Empower your strategies with our Net Present Value Model: Reata Pharmaceuticals Inc's Omaveloxolone report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Reata Pharmaceuticals Inc’s Bardoxolone Methyl
Empower your strategies with our Net Present Value Model: Reata Pharmaceuticals Inc's Bardoxolone Methyl report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Reata Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Reata Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Thematic Analysis
Global M&A Deals in 2023 – Top Themes by Sector – Thematic Intelligence
If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&As). This report analyzes the disruptive themes that have driven M&A activity in 2023 across all sectors including automotive, basic material, business and consumer services, consumer, energy, financial, healthcare, industrials, real estate, technology, media & telecoms, transportation, infrastructure, and logistics.
-
Product Insights
Alport Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Alport Syndrome - Drugs In Development, 2023’, provides an overview of the Alport Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alport Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Thematic Analysis
Pharma M&A Deals Q3 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 in the Pharma Sector
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986415 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986415 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986415 in Prostate Cancer Drug Details: BMS-986415 (DF-6002) is under development for...